NCT03988855 - An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Clostridium Difficile (C. Difficile)

Interventions

DRUG

DNV3837

Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.

Trial Locations (13)

11758

WITHDRAWN

DiGiovanna Institute for Medical Education and Research, North Massapequa

19140

WITHDRAWN

Temple University Hospital, Philadelphia

36207

WITHDRAWN

Pinnacle Research Group, Anniston

59701

RECRUITING

Mercury Street Medical, Butte

67214

WITHDRAWN

Infectious Disease Consultants (IDC) Clinical Research, Wichita

77030

WITHDRAWN

MD Anderson Cancer Center, Houston

78229

RECRUITING

Southern Star Research Institute, LLC., San Antonio

83404

RECRUITING

Snake River Research, PLLC, Idaho Falls

84112

WITHDRAWN

University of Utah, Salt Lake City

95817

RECRUITING

University of California (UC) Davis Medical Center, Sacramento

T2N 4N1

NOT_YET_RECRUITING

University of Calgary, Calgary

BC V1Y 4N7

RECRUITING

The Medical Arts Health Research Group - Kelowna, Kelowna

A1B 3V6

RECRUITING

Health Sciences Center, Eastern Health, Saint Johns